X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DIVIS LABORATORIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DIVIS LABORATORIES PFIZER/
DIVIS LABORATORIES
 
P/E (TTM) x 34.7 37.6 92.2% View Chart
P/BV x 5.1 6.1 83.6% View Chart
Dividend Yield % 0.7 0.7 90.9%  

Financials

 PFIZER   DIVIS LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-18
DIVIS LABORATORIES
Mar-18
PFIZER/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,3651,142 207.1%   
Low Rs1,625533 304.8%   
Sales per share (Unadj.) Rs430.3146.6 293.5%  
Earnings per share (Unadj.) Rs78.733.0 238.2%  
Cash flow per share (Unadj.) Rs93.238.4 242.6%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %1.01.2 84.0%  
Book value per share (Unadj.) Rs586.5222.8 263.2%  
Shares outstanding (eoy) m45.75265.47 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.65.7 81.2%   
Avg P/E ratio x25.325.3 100.0%  
P/CF ratio (eoy) x21.421.8 98.2%  
Price / Book Value ratio x3.43.8 90.5%  
Dividend payout %25.430.3 84.0%   
Avg Mkt Cap Rs m91,271222,318 41.1%   
No. of employees `0002.610.8 24.4%   
Total wages/salary Rs m3,1434,561 68.9%   
Avg. sales/employee Rs Th7,484.83,616.0 207.0%   
Avg. wages/employee Rs Th1,195.0423.8 282.0%   
Avg. net profit/employee Rs Th1,369.1814.9 168.0%   
INCOME DATA
Net Sales Rs m19,68538,915 50.6%  
Other income Rs m1,1431,134 100.7%   
Total revenues Rs m20,82840,049 52.0%   
Gross profit Rs m5,00312,617 39.7%  
Depreciation Rs m6631,425 46.5%   
Interest Rs m413 31.6%   
Profit before tax Rs m5,47912,313 44.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8783,543 53.0%   
Profit after tax Rs m3,6018,770 41.1%  
Gross profit margin %25.432.4 78.4%  
Effective tax rate %34.328.8 119.1%   
Net profit margin %18.322.5 81.2%  
BALANCE SHEET DATA
Current assets Rs m24,16745,351 53.3%   
Current liabilities Rs m9,5446,507 146.7%   
Net working cap to sales %74.399.8 74.4%  
Current ratio x2.57.0 36.3%  
Inventory Days Days55127 43.5%  
Debtors Days Days2995 30.2%  
Net fixed assets Rs m9,51421,160 45.0%   
Share capital Rs m458531 86.2%   
"Free" reserves Rs m26,37558,625 45.0%   
Net worth Rs m26,83259,156 45.4%   
Long term debt Rs m250-   
Total assets Rs m36,90067,832 54.4%  
Interest coverage x1,305.5926.8 140.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 93.0%   
Return on assets %9.812.9 75.4%  
Return on equity %13.414.8 90.5%  
Return on capital %20.420.8 98.0%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m2232,359 0.1%   
Fx outflow Rs m1,4899,042 16.5%   
Net fx Rs m-1,46623,317 -6.3%   
CASH FLOW
From Operations Rs m3,3187,759 42.8%  
From Investments Rs m-2,383-4,783 49.8%  
From Financial Activity Rs m-1,104-3,142 35.1%  
Net Cashflow Rs m-169-166 101.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 4.9 19.0 25.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.2 137.8%  
Shareholders   85,207 31,796 268.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 24, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS